Mar 15, 2019 / Reports

March 2019 Report to the Congress: Medicare Payment Policy

Research Areas:

Ambulatory Care Settings, Beneficiaries and Coverage, Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Medicare Spending and Financing, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality

Mar 15, 2019 / Fact Sheets

Fact sheet on MedPAC’s March 2019 Report to the Congress: Medicare Payment Policy

Research Areas:

Ambulatory Care Settings, Beneficiaries and Coverage, Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Medicare Spending and Financing, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality

Mar 15, 2019 / Press Releases

MedPAC releases March 2019 Report to the Congress: Medicare Payment Policy

Research Areas:

Ambulatory Care Settings, Beneficiaries and Coverage, Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Medicare Spending and Financing, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality

Mar 01, 2019 / Chapters

Chapter 14: The Medicare prescription drug program (Part D): Status report (March 2019 report)

Research Areas:

Drugs, Devices, and Tests

Mar 01, 2019 / Chapters

Chapter 16: Mandated report: Opioids and alternatives in hospital settings—Payments, incentives, and Medicare data (March 2019 report)

Research Areas:

Drugs, Devices, and Tests, Hospitals

Mar 01, 2019 / Chapters

Executive summary (March 2019 report)

Research Areas:

Beneficiaries and Coverage, Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality, Regional Issues

Jan 18, 2019 / Presentations

Future policy directions to address Medicare prescription drug spending

Research Areas:

Drugs, Devices, and Tests

Jan 17, 2019 / Presentations

The Medicare prescription drug program (Part D): Status report

Research Areas:

Drugs, Devices, and Tests, Private Plans

Jan 16, 2019 / Comment Letters

MedPAC comment on CMS’s proposed rule on modernizing Part D and Medicare Advantage to lower drug prices and reduce OOP expenses

Research Areas:

Delivery System Reforms, Drugs, Devices, and Tests, Private Plans

Nov 28, 2018 / Comment Letters

MedPAC comment on CMS’s proposed rule on requiring drug pricing transparency

Research Areas:

Delivery System Reforms, Drugs, Devices, and Tests